Skip to main content

Table 4 Pharmacokinetic parameters of edoxaban

From: Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

 Group 1
30 mg edoxaban plus
2.5 mg prasugrel
Group 2
30 mg edoxaban plus
3.75 mg prasugrel
n = 12n = 12
Edoxaban aloneEdoxaban plus
prasugrel
Edoxaban aloneEdoxaban plus
prasugrel
Cmax,ss(ng/mL)
 Mean (SD)216.0 (112.4)216.0 (80.4)191.4 (79.7)216.9 (68.1)
 Median (IQR)199.8 (127.6–300.5)187.8 (169.0–298.3)170.5 (134.5–237.3)216.6 (157.3–269.3)
AUCtau,ss(ng h/mL)
 Mean (SD)1059.4 (228.0)1068.6 (189.8)1070.4 (239.7)1088.5 (223.2)
 Median (IQR)1025.0 (924.2–1152.4)1005.8 (912.2–1216.7)992.5 (953.1–1206.7)1049.6 (930.4–1240.1)
tmax,ss(h)
 Mean (SD)1.2 (0.96)0.92 (0.70)1.0 (0.84)0.71 (0.26)
 Median (IQR)0.75 (0.50–1.5)0.75 (0.50–1.0)0.50 (0.50–1.5)0.50 (0.50–1.0)
  1. Cmax,ss steady state maximum plasma concentration, AUCtau,ss steady state area under the plasma concentration-time curve, tmax,ss steady state time to reach maximum plasma concentration, SD standard deviation, IQR interquartile range